Company President and CEO Ken Reali attributes the decline to adverse effects from the ongoing AxiaLIF physician reimbursement pressures. However, two critical papers that will provide the company with data to use during payor negotiations have been accepted to peer review journals and are expected to positively impact coverage decisions.
The company’s domestic sales were down considerably from $6 million during the first quarter of 2010 to $4.6 million during the first quarter of 2011. Net loss for the quarter was reported as $5.7 million, a decrease from the $6.4 million reported during the first quarter of last year.
Read the release on the financial report for TranS1.
Related Articles on TranS1:
TranS1 Names Ken Reali New CEO
TranS1 Receives FDA 510(k) Clearance for AxiaLIF 1L+
TranS1 Names Vice President of Research and Development
